Prevention Of Drug-Induced Osteonecrosis Of The Jaw In Cancer Patients

The occurrence of drug-induced osteonecrosis the jaw in cancer patients treated using bone-modifying medications (bisphosphonates and denosumab) is a highly relevant research problem studied by dentists, maxillofacial surgeons, oncologists. Despite large number publications, practical approaches to preventing remain be developed, which confirmed increasing prevalence severity clinical course disease. In this article, we review most significant works position papers published Russia abroad over past 10 years, as well authors’ scientific experience, order identify key reasons behind ineffective prevention suggests possible solutions. Questions concerning legal protection clinicians relation complication are discussed. Most recent achievements field laboratory diagnostics risk assessment patients, including determination bone metabolism markers, presented. following criteria for safe use bisphosphonates denosumab were identified: dental screening; monitoring; individualizing drug dosage, duration withdrawal regimens; application an interdisciplinary approach.